Table 7.
Prognostic factors for overall survival and relapse-free survival in the hepatocellular carcinoma patients with renal dysfunction
| Variable (RD patients) |
Univariate analysis (OS)
|
Multivariate analysis (OS)
|
Univariate analysis (RFS)
|
Multivariate analysis (RFS)
|
||||
|
HR (95%CI)
|
P
value
|
HR (95%CI)
|
P
value
|
HR (95%CI)
|
P
value
|
HR (95%CI)
|
P
value
|
|
| Age > 60 yr | 2.33 (1.14-5.63) | < 0.05 | 3.85 (0.81-22.53) | 0.092 | 2.08 (1.01-5.01) | < 0.05 | 0.98 (0.26-4.76) | 0.978 |
| Male | 1.37 (0.73-2.82) | 0.371 | 1.66 (0.88-3.48) | 0.122 | ||||
| HBV+ | 1.00 (0.56-1.67) | 0.995 | 1.02 (0.57-1.73) | 0.947 | ||||
| HCV+ | 0.97 (0.60-1.52) | 0.899 | 1.03 (0.64-1.63) | 0.889 | ||||
| NBNC | 1.03 (0.66-1.60) | 0.898 | 0.96 (0.61-1.50) | 0.849 | ||||
| Child-Pugh grade B | 2.16 (0.12-10.17) | 0.44 | 0.90 (0.05-4.13) | 0.919 | ||||
| Plt < 13.8 | 0.88 (0.54-1.40) | 0.598 | 0.76 (0.46-1.22) | 0.257 | ||||
| PT < 80 | 0.89 (0.47-1.57) | 0.706 | 1.05 (0.57-1.81) | 0.858 | ||||
| Alb < 4.0 | 1.25 (0.80-1.95) | 0.321 | 1.23 (0.78-1.92) | 0.376 | ||||
| T-bil > 1.2 | 0.87 (0.30-2.01) | 0.772 | 1.03 (0.40-2.18) | 0.95 | ||||
| AST > 38 | 1.15 (0.74-1.79) | 0.534 | 1.31 (0.85-2.05) | 0.223 | ||||
| ALT > 44 | 0.71 (0.43-1.14) | 0.162 | 1.21 (0.76-1.90) | 0.421 | ||||
| ChE < 168 | 2.40 (1.22-4.32) | < 0.01 | 1.06 (0.31-3.15) | 0.921 | 3.15 (1.59-5.79) | < 0.01 | 2.21 (0.17-1.35) | 0.147 |
| ICGR15 > 15 | 0.94 (0.60-1.48) | 0.800 | 1.36 (0.87-2.14) | 0.176 | ||||
| HbA1c > 5.6 | 1.49 (0.87-2.55) | 0.145 | 0.94 (0.57-1.56) | 0.823 | ||||
| AFP > 10 | 1.51 (0.97-2.39) | 0.068 | 2.07 (1.32-3.28) | < 0.01 | 0.79 (0.29-2.03) | 0.634 | ||
| AFP-L3 > 10 | 2.97 (1.74-5.01) | < 0.0001 | 2.57 (0.99-6.70) | 0.051 | 2.21 (1.33-3.59) | < 0.01 | 2.22 (0.87-5.98) | 0.095 |
| PIVKA-II > 40 | 1.85 (1.17-3.00) | < 0.01 | 2.57 (0.64-11.50) | 0.186 | 1.53 (0.97-2.46) | 0.067 | ||
| Operative time > Ave | 0.96 (0.62-1.50) | 0.868 | 0.98 (0.62-1.53) | 0.916 | ||||
| Blood loss > Ave | 1.31 (0.78-2.13) | 0.282 | 1.17 (0.70-1.89) | 0.533 | ||||
| Anatomical resection | 1.06 (0.64-1.85) | 0.833 | 0.79 (0.48-1.37) | 0.391 | ||||
| Resected liver weight > Ave | 2.05 (1.18-3.44) | < 0.01 | 0.99 (0.37-2.66) | 0.978 | 1.53 (0.87-2.59) | 0.137 | ||
| Tumor size > Ave | 1.94 (1.18-3.10) | < 0.01 | 1.06 (0.33-3.30) | 0.918 | 1.88 (1.14-3.04) | < 0.05 | 1.86 (0.63-5.40) | 0.258 |
| Tumor number > 1 | 2.13 (1.30-3.45) | < 0.01 | 2.44 (1.04-5.75) | < 0.05 | 3.46 (2.04-5.85) | < 0.0001 | 3.77 (1.61-8.97) | < 0.01 |
| Pathological grade (mod-por) | 1.23 (0.70-2.34) | 0.505 | 1.32 (0.76-2.47) | 0.337 | ||||
| Vascular invasion (Vp+, Vv+) | 4.92 (2.21-9.84) | < 0.0001 | 1.88 (0.61-5.14) | 0.26 | 4.08 (1.86-8.00) | < 0.01 | 1.89 (0.70-4.60) | 0.198 |
| Liver fibrosis score 3, 4 | 1.29 (0.80-2.03) | 0.278 | 1.37 (0.86-2.16) | 0.186 | ||||
OS: Overall survival; RFS: Recurrence-free survival; HR: Hazard ratio; CI: Confidence interval; RD: Renal dysfunction; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NBNC: Non-hepatitis B virus or hepatitis C virus; Plt: Platelet counts; PT: Prothrombin time; Alb: Serum albumin; T-bil: Total bilirubin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ChE: Choline esterase; ICGR15: Indocyanine green rate at 15 min; HbA1c: Hemoglobin A1c; BUN: Blood urea nitrogen; Cr: Creatinine; AFP: Alpha-fetoprotein; AFP-L3: Alpha-fetoprotein isoform, lectin affinity; PIVKA-II: Protein-induced vitamin K absence-II; Ave: Average; Mod: Moderately differentiated; por: Poorly differentiated; Vp: Portal vein invasion; Vv: Hepatic vein invasion.